ReviewCurrent infectious disease reports2016
Update on the Diagnosis and Management of Neurocysticercosis.
Review in Current infectious disease reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 43 citations in OpenAlex.
- Prevalence of neurocysticercosis and its characteristics among people with epileptic seizures and progressively worsening severe headaches in 60 villages in three provinces of Burkina Faso.PLoS neglected tropical diseases · 2026Trial
- Exploring Geophagy as a Risk Factor for Neurocysticercosis: A Case Series from the Democratic Republic of the Congo.The American journal of tropical medicine and hygiene · 2025Article
- Successful Gastrografin Vermifugation for Taenia saginata-associated Appendicitis.Internal medicine (Tokyo, Japan) · 2024Article
- Silent Intruder: Unusual Presentation of Neurocysticercosis in an HIV-Infected Patient from the Far Northern Brazilian Amazon.Medicina (Kaunas, Lithuania) · 2024Article
- Article
- Surgical management of intraventricular neurocysticercosis: Two cases treated through transcallosal interhemispheric approach.Surgical neurology international · 2024Article
- Human Neurocysticercosis: An Overview.Pathogens (Basel, Switzerland) · 2022Review
- Update on the diagnosis and management of neurocysticercosis.Arquivos de neuro-psiquiatria · 2022Review
- Subarachnoid Neurocysticercosis Presenting as a New-Onset Seizure in an Immigrant From Guatemala.Cureus · 2021Article
- Chronic administration of cryptolepine nanoparticle formulation alleviates seizures in a neurocysticercosis model.Current research in pharmacology and drug discovery · 2021Article
- The Burden of Neurocysticercosis at a Single New York Hospital.Journal of pathogens · 2020Article
- Use of Ivermectin in Neurocysticercosis: A Case Report.The American journal of case reports · 2018Review
- Not just another diplopia: neurocysticercosis in a postpartum woman.BMJ case reports · 2018Article
- Neurocysticercosis in Pregnancy.AJP reports · 2018Article
- Human Extraparenchymal Neurocysticercosis: The Control of Inflammation Favors the Host…but Also the Parasite.Frontiers in immunology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neurocysticercosis is an important cause of seizures worldwide and is endemic in most of Latin America, Sub-Saharan Africa, Southeast Asia, India, and China. Neurocysticercosis has profoundly different disease manifestations varying from asymptomatic presentation to life-threatening hydrocephalus. Clinical manifestations, pathogenesis, diagnostic methods, and optimal treatment vary with the location, number of lesions, and host response. Diagnosis is based on a combination of clinical presentation, neuroimaging findings, history of exposure, and serologic testing. Initial therapy should be focused on symptom management including seizure control and management of increased intracranial pressure. Emerging data are demonstrating that the optimal management approach varies with stage. Single enhancing or cystic lesions should be treated with albendazole and steroids. Patients with more than two cystic lesions should be treated with combination therapy with albendazole and praziquantel, whereas patients with hydrocephalus benefit from surgical management, especially with minimally invasive approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.